AbbVie Inc. (ABBV) SEC Filings & Earnings Calls

IPR&D expense reduces EPS; non-recurring but impacts guidance.

“acquired IPR&D and milestones expense of $216 million ... unfavorable impact of $0.11”

Dilution from acquisition impacts near-term EPS; accretion expected in 2032.

“AbbVie expects its acquisition of Apogee to negatively impact adjusted diluted earnings per share (EPS) by $0.14 in 2026 (partial year) and approximately $0.46 in 2027, with accretion beginning in 2032.” · word for word

Increased leverage from $10B debt issuance

“Issuance of $10 billion in senior notes increases debt burden”

High contingent consideration liability

“Contingent consideration $27,495 million as of June 30, 2026, with $3,905 million change in fair value recognized in earnings.”

Large debt issuance

“Issued $8.0 billion aggregate principal amount of unsecured senior notes in March 2026.”

Customer concentration

“Three U.S. wholesalers accounted for 82% of net accounts receivable as of June 30, 2026.”

Humira revenue continues to decline (-35.9%) due to biosimilar competition.

“Global Humira Net Revenues Were $756 Million, a Decrease of 35.9 Percent” · word for word

Oncology portfolio revenue declined (-1.5%) driven by Imbruvica (-29.4%).

“Global Net Revenues from the Oncology Portfolio Were $1.650 Billion, a Decrease of 1.5 Percent” · word for word

Aesthetics portfolio growth nearly flat (+0.3% reported, -0.9% operational), with Juvederm declining.

“Global Net Revenues from the Aesthetics Portfolio Were $1.282 Billion, an Increase of 0.3 Percent on a Reported Basis, or a Decrease of 0.9 Percent on an Operational Basis” · word for word

Guidance narrowed downward by $0.04 at midpoint, partly due to $0.14 dilutive impact from Apogee acquisition.

“Updates 2026 Adjusted Diluted EPS Guidance Range from $13.91 - $14.11 to $13.87 - $14.07; Now Includes a $0.14 per Share Dilutive Impact Related to the Proposed Acquisition of Apogee Therapeutics” · word for word

Acquired IPR&D and milestones expense creates earnings volatility

“AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing” · word for word

Integration risk and potential failure to obtain regulatory or stockholder approval.

“risk that the proposed acquisition may not close in the anticipated timeframe or at all” · word for word

Contingent consideration liability volatility

“Change in fair value of contingent consideration liabilities $2,387 million for Q1 2026 vs $1,518 million for Q1 2025.” · word for word

Litigation accrual

“The recorded accrual balance for litigation was approximately $1.7 billion as of March 31, 2026.” · word for word

Humira biosimilar erosion

“Humira revenue not explicitly stated but known to be declining; litigation also targets Humira pricing.”

High debt levels

“Long-term debt $64,532 million plus current portion $8,326 million; total debt $72,858 million.”

GAAP EPS decline of 45.8% due to acquired IPR&D and milestones expense; Humira continues to decline.

“GAAP diluted EPS $0.39, down 45.8%; Humira net revenues down 38.6%.”

Large IPR&D expense impacting earnings guidance

“$744M pre-tax expense reduces adjusted EPS by $0.41.”

Increased leverage with $8.0B in new debt; interest expense will rise.

“Issued $8.0B aggregate principal amount of senior notes across multiple tranches.”

Increased debt leverage from new issuance

“Underwriting agreement for debt securities”

Humira biosimilar erosion

“Humira faces direct biosimilar competition globally and AbbVie will continue to face competitive pressure from these biologics and from orally administered products.” · word for word

Contingent consideration liability

“Contingent consideration liabilities $25,374 million as of Dec 31, 2025.”

Aesthetics demand weakness

“Net revenues for Botox Cosmetic decreased 4% in 2025. In the United States, Botox Cosmetic net revenues decreased 11% primarily driven by ... decreased consumer demand.” · word for word

Pipeline failure risk

“The global Phase 3 VERONA trial evaluating Venclexta in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome did not meet the primary endpoint of overall survival.” · word for word

Humira revenue continues to decline due to biosimilar competition.

“Global Humira Net Revenues Were $4.540 Billion (down from prior year)” · word for word

Aesthetics portfolio revenue declined 6.1% in FY2025.

“Full-Year Global Net Revenues from the Aesthetics Portfolio Were $4.860 Billion, a Decrease of 6.1 Percent” · word for word

Large IPR&D expense reduces EPS; uncertainty in forecasting such expenses.

“Acquired IPR&D and milestones expense of $1.3B; AbbVie does not forecast such expenses due to uncertainty.” · word for word

Acquired IPR&D expense volatility

“Acquired IPR&D and milestones $2,680 million for Q3 2025 vs $82 million for Q3 2024.”

Impairment risk on intangible assets

“Impairment of intangible assets $847 million for 9M 2025 vs $0 for 9M 2024.”

Equity deficit and high leverage

“Total stockholders' equity (deficit) $(2,642) million at Sep 30, 2025.”

GAAP EPS significantly impacted by acquired IPR&D and milestones expense ($1.50 per share).

“These Results Include an Unfavorable Impact of $1.50 Per Share Related to Acquired IPR&D and Milestones Expense.” · word for word